AstraZeneca Results Presentation Deck
Emerging Markets
Total revenue $12.3bn (including Vaxzevria¹ revenue)
Emerging markets +10%²
China +4%; Ex-China EMs +21%²
$m
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
Q4
2019
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
2020
China Ex-China EMS COVID-19 vaccine sales
2021
●
●
Diversified growth across geographies
Launches in ex-China Emerging Markets progressing well
Oncology $3.2bn, +6%: Tagrisso $1.3bn, up 6% continued
impact from NRDL inclusion in China, offset by solid
growth ex-China for Lynparza, Imfinzi, and Tagrisso
CVRM $3.8bn, +12%: continued strong growth for Forxiga
($1.2bn, +70%) driven by HF and CKD launches
Respiratory & Immunology $1.7bn, +4%: Pulmicort
($770m, -9%) due to VBP inclusion in October. Symbicort
growth ($609m, +4%) mainly driven by ex-China
25 1. Vaxzevria Total Revenue' also includes Collaboration Revenue from sub-licensees that produce and supply the AstraZeneca COVID-19 Vaccine under their own trademarks. 2. Growth number calculated excluding revenue of the
Vaxzevria. Growth including Vaxzevria is as follows: Emerging Market total revenue growth +36%, China +4%; Other EMs +89%.
3View entire presentation